Posted by Michael Wonder on 17 Sep 2022
Leo Pharma receives positive CHMP opinion of Adtralza (tralokinumab) for the treatment of adolescents with moderate to severe atopic dermatitis
16 September 2022 - Recommendation supported by data from the Phase 3 ECZTRA 6 trial.
Leo Pharma today announced that the CHMP of the EMA has adopted a positive opinion recommending to extend the approval of Adtralza (tralokinumab) in the European Union to include adolescents aged 12 to 17 with moderate to severe atopic dermatitis who are candidates for systemic therapy.
